Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis.
Predictors of static balance in ambulatory persons with multiple sclerosis.
Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica.
[Optic neuritis in childhood. A pediatric series, literature review and treatment approach].
Infection.
Navigating the Decision Space: Shared Medical Decision Making as Distributed Cognition.
Daclizumab (Zinbryta) for multiple sclerosis.
Safety, Tolerability, and Immunogenicity of Interferons.
Evidence in sexual assault case ruled out.
Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies.
Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
Specific immune complexes augment in vitro acetylcholine receptor-specific T-cell proliferation.
Potential Benefit of the Charge-Stabilized Nanostructure Saline RNS60 for Myelin Maintenance and Repair.
Metabolic determinants of the immune modulatory function of neural stem cells.
Reduced fecal GABA levels in multiple sclerosis patients.
Statistical estimation of white matter microstructure from conventional MRI.
Performance of F2 B6x129 hybrid mice in the Morris water maze, latent inhibition and prepulse inhibition paradigms: Comparison with C57Bl/6J and 129sv inbred mice.
Arzerra receives approval in Japan
Neuromyelitis optica accompanied by nephrotic syndrome and autoimmune-related pancytopenia.
MEG evaluation of pico-Tesla external TMS on multiple sclerosis patients.
Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency.
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
Genetic background modulates outcome of therapeutic amyloid peptides in treatment of neuroinflammation.
NG2-glia, More Than Progenitor Cells.

Pages